Suppr超能文献

加利福尼亚州第64号提案通过后医用大麻及医用/娱乐用大麻的联合使用情况

Medicinal and combined medicinal/recreational cannabis use in California following the passage of Proposition 64.

作者信息

Ageze Daniel, Dell'Acqua Renee, Marcotte Thomas D, Rybar Jill, Baird Sara, Gold Alice, Shaughnessy Tom, Lanin-Kettering Ilene, Hill Linda

机构信息

Herbert Wertheim School of Public Health and Human Longevity Science, UC San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0994, USA.

Department of Psychiatry, Center for Medicinal Cannabis Research, UC San Diego, 220 Dickinson Street, Suite B, MC8231, San Diego, CA, 92103-8231, USA.

出版信息

J Cannabis Res. 2025 Jul 12;7(1):44. doi: 10.1186/s42238-025-00285-9.

Abstract

BACKGROUND

Proposition 64, the Adult Use of Marijuana Act of 2016, reshaped cannabis use in California. This study explores the use patterns of people who use cannabis for medicinal-only and combined medicinal and recreational use after implementation of Proposition 64.

METHODS

A quantitative, population-based online questionnaire included 4,020 current cannabis users, 523 former users, and 635 non-users. This analysis focuses on participants who self-identified as using cannabis for medicinal-only (n = 711) or both medicinal and recreational (M + R, n = 1719) purposes.

RESULTS

Sixty one percent of current cannabis users report medicinal use. Medicinal-only users were more likely to be female (OR 1.6, p < 0.001), have kids in household (OR 1.5, p < 0.001), and began cannabis use later (mean age 34 vs. 23, p < 0.001). Pain relief was the predominant reason for use, followed by sleep, anxiety, and stress relief. While both groups reported positive effects, M + R users experienced more negative side effects. Fewer medicinal-only users cited a desire to "feel the high," (42% vs. 75% M + R, p < 0.001). Medicinal-only users felt less comfortable discussing cannabis with primary care providers than M + R users (75% vs 83%, p < 0.01). All users were more likely to seek information online (44-57%) or from friends/family (47-52%) than health professionals (26-27%). Dispensaries were the main cannabis source for both medicinal groups (72% M vs. 84% M + R, p < 0.01), with licensure being very or extremely important (72% M, 66% M + R, p < 0.01). Monthly spending for medicinal-only users was lower ($127 vs. $186 for M + R, p < 0.001), and they were more likely than M + R users to wait before feeling safe to drive after using cannabis.

CONCLUSION

People who use medicinal cannabis alone vary in key areas from people who use cannabis for both medicinal and recreational reasons. The need for better patient-provider relationships and clinically informed guidance is evident to support medicinal cannabis users.

摘要

背景

2016年的《第64号提案:成人使用大麻法案》重塑了加利福尼亚州的大麻使用情况。本研究探讨了在第64号提案实施后,仅将大麻用于医疗用途以及同时用于医疗和娱乐用途的人群的使用模式。

方法

一项基于人群的定量在线调查问卷涵盖了4020名当前大麻使用者、523名曾经的使用者和635名非使用者。本分析聚焦于那些自我认定仅将大麻用于医疗用途(n = 711)或同时用于医疗和娱乐用途(M+R,n = 1719)的参与者。

结果

61%的当前大麻使用者报告有医疗用途。仅用于医疗的使用者更可能为女性(比值比1.6,p < 0.001),家中有孩子(比值比1.5,p < 0.001),且开始使用大麻的时间较晚(平均年龄34岁对23岁,p < 0.001)。缓解疼痛是使用大麻的主要原因,其次是助眠、缓解焦虑和压力。虽然两组都报告有积极效果,但M+R组使用者经历的负面副作用更多。仅用于医疗的使用者中提及“体验快感”意愿的较少(42%对M+R组的75%,p < 0.001)。与M+R组使用者相比,仅用于医疗的使用者在与初级保健提供者讨论大麻时感觉更不自在(75%对83%,p < 0.01)。所有使用者从网上(44 - 57%)或朋友/家人(47 - 52%)获取信息的可能性都高于从医疗专业人员处获取信息(26 - 27%)。药房是两个医疗组获取大麻的主要来源(医疗组为72%,M+R组为84%,p < 0.01),执照非常重要或极其重要(医疗组为72%,M+R组为66%,p < 0.01)。仅用于医疗的使用者每月花费较低(127美元对M+R组的186美元,p < 0.001),且与M+R组使用者相比,他们在使用大麻后更可能等待一段时间才觉得开车安全。

结论

仅使用医用大麻的人群在关键方面与同时将大麻用于医疗和娱乐用途的人群有所不同。显然需要建立更好的医患关系并提供基于临床的指导,以支持医用大麻使用者。

相似文献

3
Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.
Cochrane Database Syst Rev. 2023 Jan 9;1(1):CD014908. doi: 10.1002/14651858.CD014908.pub2.
4
Psychosocial interventions for cannabis use disorder.
Cochrane Database Syst Rev. 2016 May 5;2016(5):CD005336. doi: 10.1002/14651858.CD005336.pub4.
7
Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder.
Cochrane Database Syst Rev. 2016 Apr 4;4(4):CD010204. doi: 10.1002/14651858.CD010204.pub2.
8
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
10
Technological aids for the rehabilitation of memory and executive functioning in children and adolescents with acquired brain injury.
Cochrane Database Syst Rev. 2016 Jul 1;7(7):CD011020. doi: 10.1002/14651858.CD011020.pub2.

本文引用的文献

1
Medicinal cannabis use among young adults during California's transition from legalized medical use to adult-use: a longitudinal analysis.
Am J Drug Alcohol Abuse. 2024 Mar 3;50(2):229-241. doi: 10.1080/00952990.2024.2308098. Epub 2024 Feb 26.
3
Impact of Recreational Cannabis Legalization on Opioid Prescribing and Opioid-Related Hospital Visits in Colorado: an Observational Study.
J Gen Intern Med. 2023 Sep;38(12):2726-2733. doi: 10.1007/s11606-023-08195-3. Epub 2023 Jun 20.
4
Local Laws Regulating Cannabis in California Two Years Post Legalization: Assessing Incorporation of Lessons from Tobacco Control.
Cannabis. 2022 Nov 21;5(3):47-60. doi: 10.26828/cannabis/2022.03.005. eCollection 2022.
5
Physicians' Attitudes and Practices Regarding Cannabis and Recommending Medical Cannabis Use.
Cannabis Cannabinoid Res. 2024 Aug;9(4):e1048-e1055. doi: 10.1089/can.2022.0324. Epub 2023 Apr 25.
6
Cannabis use in Attention - Deficit/Hyperactivity Disorder (ADHD): A scoping review.
J Psychiatr Res. 2023 Jan;157:239-256. doi: 10.1016/j.jpsychires.2022.11.029. Epub 2022 Nov 25.
7
Online survey of medicinal cannabis users: Qualitative analysis of patient-level data.
Front Pharmacol. 2022 Sep 6;13:965535. doi: 10.3389/fphar.2022.965535. eCollection 2022.
8
Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada.
Psychopharmacology (Berl). 2022 May;239(5):1509-1519. doi: 10.1007/s00213-021-06047-8. Epub 2022 Jan 12.
9
Sociodemographic Characteristics Associated With and Prevalence and Frequency of Cannabis Use Among Adults in the US.
JAMA Netw Open. 2021 Nov 1;4(11):e2136571. doi: 10.1001/jamanetworkopen.2021.36571.
10
Demographics, Perceptions, and Use of Medical Marijuana among Patients in Florida.
Med Cannabis Cannabinoids. 2020 Dec 22;4(1):13-20. doi: 10.1159/000512342. eCollection 2021 Jun.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验